ProCE Banner Activity

Real-World Outcomes With Immune Checkpoint Inhibitors in Patients With Advanced NSCLC and Autoimmune Disease

Slideset Download
Conference Coverage
Treatment with ICI-based therapy showed comparable safety and no significant differences in clinical efficacy for patients with vs without a history of autoimmune disease.

Released: June 06, 2019

Expiration: June 04, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro